Oxurion NV (OXUR) - Total Liabilities

Latest as of June 2025: €16.98 Million EUR ≈ $19.85 Million USD

Based on the latest financial reports, Oxurion NV (OXUR) has total liabilities worth €16.98 Million EUR (≈ $19.85 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Oxurion NV's assets to evaluate the company's liquid asset resilience ratio.

Oxurion NV - Total Liabilities Trend (2006–2024)

This chart illustrates how Oxurion NV's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Oxurion NV total assets.

Oxurion NV Competitors by Total Liabilities

The table below lists competitors of Oxurion NV ranked by their total liabilities.

Company Country Total Liabilities
K3 Business Technology Group PLC
LSE:KBT
UK GBX15.84 Million
Tan Delta Systems PLC
LSE:TAND
UK GBX335.02K
Exploitasi Energi Indonesia
JK:CNKO
Indonesia Rp2.05 Trillion
Panamax AG
F:ICP
Germany €365.14K
Aquila Energy Efficiency Trust PLC
LSE:AEET
UK GBX892.00K
Kazera Global PLC
LSE:KZG
UK GBX856.00K
First Eagle Alternative Capital BDC Inc
NYSE:FCRX
USA $916.10 Million

Liability Composition Analysis (2006–2024)

This chart breaks down Oxurion NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Oxurion NV balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.17 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.41 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oxurion NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oxurion NV (2006–2024)

The table below shows the annual total liabilities of Oxurion NV from 2006 to 2024.

Year Total Liabilities Change
2024-12-31 €16.75 Million
≈ $19.59 Million
-15.11%
2023-12-31 €19.74 Million
≈ $23.07 Million
+19.06%
2022-12-31 €16.58 Million
≈ $19.38 Million
-17.05%
2021-12-31 €19.98 Million
≈ $23.36 Million
+116.37%
2020-12-31 €9.24 Million
≈ $10.80 Million
-21.22%
2019-12-31 €11.72 Million
≈ $13.71 Million
+22.71%
2018-12-31 €9.55 Million
≈ $11.17 Million
-44.06%
2017-12-31 €17.08 Million
≈ $19.97 Million
+45.03%
2016-12-31 €11.78 Million
≈ $13.77 Million
+31.87%
2015-12-31 €8.93 Million
≈ $10.44 Million
-29.69%
2014-12-31 €12.70 Million
≈ $14.85 Million
+2.58%
2013-12-31 €12.38 Million
≈ $14.48 Million
+10.50%
2012-12-31 €11.21 Million
≈ $13.10 Million
+1.31%
2011-12-31 €11.06 Million
≈ $12.93 Million
+132.99%
2010-12-31 €4.75 Million
≈ $5.55 Million
-36.72%
2009-12-31 €7.50 Million
≈ $8.77 Million
+55.95%
2008-12-31 €4.81 Million
≈ $5.62 Million
+35.04%
2007-12-31 €3.56 Million
≈ $4.16 Million
+73.25%
2006-12-31 €2.06 Million
≈ $2.40 Million
--

About Oxurion NV

BR:OXUR Belgium Biotechnology
Market Cap
$248.85K
€212.86K EUR
Market Cap Rank
#31276 Global
#112 in Belgium
Share Price
€0.00
Change (1 day)
-7.69%
52-Week Range
€0.00 - €0.02
All Time High
€102000.00
About

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more